ADC Therapeutics SA (ADCT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$231.0M
Cash & Equivalents
$29.7M
Quarterly Burn Rate
23 mo
Est. Cash Runway
$164M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-11 | Phase2 Readout | — |
| 2026-12-31 | Phase1 Readout | — |
| 2027-01-12 | Phase3 Readout | — |
| 2027-01-29 | Phase3 Readout | — |
Active Clinical Trials (22)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Ute... | PHASE3 | Recruiting | 480 |
| NCT04162210 | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants Wit... | PHASE3 | Active Not Recruiting | 325 |
| NCT05911295 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | PHASE3 | Active Not Recruiting | 412 |
| NCT04484623 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple ... | PHASE3 | Active Not Recruiting | 302 |
| NCT05609968 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Particip... | PHASE3 | Active Not Recruiting | 614 |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Al... | PHASE3 | Recruiting | 1,123 |
| NCT07070232 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon... | PHASE2 | Recruiting | 980 |
| NCT04879329 | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | PHASE2 | Recruiting | 372 |
| NCT07258407 | A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer | PHASE2 | Recruiting | 180 |
| NCT07111520 | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Benefi... | PHASE2 | Recruiting | 420 |
| NCT06953089 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | PHASE2 | Recruiting | 450 |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | PHASE2 | Active Not Recruiting | 320 |
| NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327... | PHASE2 | Recruiting | 375 |
| NCT06892548 | A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327... | PHASE2 | Recruiting | 594 |
| NCT04802759 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | PHASE2 | Recruiting | 316 |
| NCT07058688 | A Study of NTRX-07 in Participants With Alzheimer's Disease | PHASE2 | Recruiting | 48 |
| NCT07229313 | A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors | PHASE1 | Recruiting | 76 |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | PHASE1 | Recruiting | 250 |
| NCT05142189 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie... | PHASE1 | Recruiting | 320 |
| NCT07362888 | First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors | PHASE1 | Recruiting | 180 |
| NCT06596473 | A Study of BG-C477 in Participants With Advanced Solid Tumors | PHASE1 | Recruiting | 310 |
| NCT07238075 | ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers | PHASE1 | Recruiting | 290 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.